COST-EFFECTIVENESS OF GUANFACINE EXTENDED-RELEASE AS AN ADJUNCTIVE THERAPY TO A LONG-ACTING STIMULANT VERSUS LONG-ACTING STIMULANT MONOTHERAPY FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN CANADA

被引：0

作者：

Lachaine, J. ^{[1
]}

Sikirica, V ^{[2
]}

Mathurin, K. ^{[1
]}

机构：

[1] Univ Montreal, Montreal, PQ, Canada

[2] Shire Dev LLC, Wayne, PA USA

来源：

VALUE IN HEALTH | 2014年 / 17卷 / 03期

关键词：

D O I：

10.1016/j.jval.2014.03.1251

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PMH32

引用

页码：A214 / A214

页数：1

共 50 条

[1] Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD
Lachaine, Jean
Sikirica, Vanja
Mathurin, Karine
BMC PSYCHIATRY, 2016, 16
[2] Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD
Jean Lachaine
Vanja Sikirica
Karine Mathurin
BMC Psychiatry, 16
[3] Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents
Sikirica V.
Haim Erder M.
Xie J.
MacAulay D.
Diener M.
Hodgkins P.
Wu E.Q.
PharmacoEconomics, 2012, 30 (8) : e1 - e15
[4] Innovations in attention-deficit/hyperactivity disorder pharmacotherapy: Long-acting stimulant and nonstimulant treatments
Stein, MA
AMERICAN JOURNAL OF MANAGED CARE, 2004, 10 (04): : S89 - S98
[5] Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder
Faraone, Stephen V.
EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (09) : 1565 - 1574
[6] COST-EFFECTIVENESS OF GUANFACINE EXTENDED-RELEASE VERSUS ATOMOXETINE FOR THE TREATMENT OF CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN CANADA
Lachaine, J.
Sikirica, V
Mathurin, K.
VALUE IN HEALTH, 2014, 17 (03) : A213 - A214
[7] Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder
Erder, M.
Xie, Jipan
Signorovitch, James
Chen, Kristina
Hodgkins, Paul
Lu, Mei
Wu, Eric
Sikirica, Vanja
APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2012, 10 (06) : 381 - 395
[8] A COST-EFFECTIVENESS ANALYSIS OF GUANFACINE EXTENDED-RELEASE TREATMENT IN PEDIATRIC ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
Maeda, S.
Shimozuma, K.
Takeda, Y.
VALUE IN HEALTH, 2016, 19 (07) : A841 - A841
[9] The Impact of Long-Acting Medications on Attention-Deficit/Hyperactivity Disorder Treatment Disparities
Saloner, Brendan
Fullerton, Catherine
McGuire, Thomas
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2013, 23 (06) : 401 - 409
[10] The impact of adjunctive guanfacine extended release on stimulant adherence in children/adolescents with attention-deficit/hyperactivity disorder
Meyers, Juliana
Gajria, Kavita
Candrilli, Sean D.
Fridman, Moshe
Sikirica, Vanja
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2017, 6 (02) : 109 - 125

← 1 2 3 4 5 →